ProCE Banner Activity

HPTN 083: Updated Safety and Efficacy of Long-Acting Injectable CAB vs Daily Oral FTC/TDF as HIV PrEP in MSM and TGW

Slideset Download
Conference Coverage
Additional 1 year of unblinded follow-up of HPTN 083 study continues to support superiority of long-acting injectable cabotegravir vs daily oral FTC/TDF in reducing incident HIV infection among MSM and TGW at high risk of HIV infection.

Released: February 18, 2022

Expiration: February 17, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare